Back to homepage

Tag "Major depressive disorder"

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

Authors: James M Martinez, Margaret B Ferguson, Beth A Pangallo, Tina M Oakes, JonDavid Sparks, Mary Anne Dellva, Qi Zhang, Peng Liu, Mark Bangs, Jonna Ahl, Celine Goldberger

This analysis confirms that the tolerability and safety profile of edivoxetine as adjunctive treatment to SSRI antidepressants was consistent with its norepinephrine reuptake inhibitor mechanism of action, and was comparable with edivoxetine monotherapy treatment in patients with major depressive disorder.

More

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

Authors: Susan G Ball, Durisala Desaiah, Qi Zhang, Michael E Thase, David G S Perahia

Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This review provides evidence that duloxetine 60 mg QD is effective for the treatment of adult patients with MDD in the short- and long-term phases of treatment. Duloxetine 60 mg QD also represents a viable choice of treatment for those patients with painful physical symptoms associated with MDD.

More